Evidence · Research paper
Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
- Infection and sepsis
- Medical
- Meningitis and encephalitis
- Neurology
- Sepsis
This paper is from 2018, more than five years ago. Newer evidence may have been published since.
Summary
Population pharmacokinetic analysis of meropenem in plasma and CSF using data from the NeoMero-1 (late-onset neonatal sepsis) and NeoMero-2 (neonatal meningitis) studies. A one-compartment model with allometric scaling and maturation described disposition, and CSF penetration was low but increased with higher CSF protein concentrations. Simulations suggested prolonged infusions improved plasma target attainment but reduced CSF exposure, favouring more frequent dosing when CNS targets matter. Relevant to clinicians managing antimicrobial dosing in neonates and young infants with sepsis or meningitis.
Summary written for PICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to PICUlearn members, and Peeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.